Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc. (OTCMKTS:MCUJF – Get Rating) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 100 shares, a decline of 66.7% from the July 31st total of 300 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is presently 0.0 days.
Medure Inc.是8月份空頭股數大幅下跌的目標。截至8月15日，空頭股數共有100股，較7月31日的300股下降了66.7%。以16,600股的平均成交量計算，目前的天數與回補比率為0.0天。
Medicure Trading Down 6.2 %
藥品降價6.2%
Shares of MCUJF stock opened at $0.79 on Friday. The company's fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $0.84. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.61 and a quick ratio of 1.18. Medicure has a 1 year low of $0.64 and a 1 year high of $1.10. The stock has a market capitalization of $8.10 million, a price-to-earnings ratio of 14.04 and a beta of 0.83.
MCUJF股票上週五開盤報0.79美元。該公司的50日簡單移動均線切入位為0.84美元，200日簡單移動均線切入位為0.84美元。該公司的債務權益比為0.04，流動比率為1.61，速動比率為1.18。Medicure的一年低點為0.64美元，一年高位為1.10美元。該股市值為810萬美元，市盈率為14.04倍，貝塔係數為0.83。
Medicure (OTCMKTS:MCUJF – Get Rating) last issued its earnings results on Monday, May 30th. The company reported $0.04 earnings per share (EPS) for the quarter. Medicure had a net margin of 3.40% and a return on equity of 4.28%. The business had revenue of $4.51 million for the quarter.
Medicure(OTCMKTS：MCUJF-GET Rating)最近一次發佈收益報告是在5月30日(星期一)。該公司公佈該季度每股收益(EPS)為0.04美元。Medicure的淨利潤率為3.40%，股本回報率為4.28%。該業務本季度的收入為451萬美元。
About Medicure
關於Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Pharmure Inc是一家生物製藥公司，從事加拿大和美國心血管市場人類療法的研究、開發和商業化。該公司營銷和分銷阿格列斯特注射劑，這是一種糖蛋白GP IIb/IIIa受體拮抗劑，用於治療急性冠脈綜合徵，包括不穩定心絞痛和非Q波心肌梗死。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Medicure (MCUJF)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
- 免費獲取StockNews.com的醫療研究報告(MCUJF)
- 艾伯維公司。應該在你的股息投資組合中佔有一席之地嗎？
- PayPal是盈利後價格跳漲後的買入嗎？
- 威廉姆斯-索諾馬的高端消費者仍在消費
- 雪花股票因業績強勁而飆升
- 股價下跌40%的Shockwave Stunts：這是買入嗎？
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
接受《醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Medicure和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。